Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Sensitive Prostate Cancer”

208 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 208 results

Large-scale testing (Phase 3)Looking for participantsNCT05956639
What this trial is testing

Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
The First Affiliated Hospital with Nanjing Medical University 100
Large-scale testing (Phase 3)Looking for participantsNCT07028853
What this trial is testing

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Who this might be right for
Metastatic Castration Sensitive Prostate Cancer (mCSPC)Hormone Sensitive Prostate CancerProstate Cancer+1 more
Pfizer 1,000
Not applicableStudy completedNCT01366053
What this trial is testing

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Who this might be right for
Prostate Cancer
CMX Research 125
Testing effectiveness (Phase 2)Study completedNCT04332744
What this trial is testing

Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)

Who this might be right for
Metastatic Prostate Cancer
MedSIR 54
Large-scale testing (Phase 3)Active Not RecruitingNCT04493853
What this trial is testing

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

Who this might be right for
Hormone-Sensitive Prostate Cancer
AstraZeneca 1,012
Large-scale testing (Phase 3)Active Not RecruitingNCT04497844
What this trial is testing

Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)

Who this might be right for
Prostatic Neoplasms
Janssen Research & Development, LLC 696
Testing effectiveness (Phase 2)Study completedNCT03336983
What this trial is testing

Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients

Who this might be right for
Prostate CancerBone Metastases
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia 126
Large-scale testing (Phase 3)Looking for participantsNCT06496581
What this trial is testing

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

Who this might be right for
Prostate Cancer Metastatic
UNICANCER 500
Not applicableLooking for participantsNCT07395804
What this trial is testing

How Darolutamide Plus Hormone Therapy Works for Men With Advanced Prostate Cancer in Everyday Medical Practice in Germany

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Bayer 500
Not applicableTemporarily pausedNCT07146113
What this trial is testing

Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federation

Who this might be right for
Prostate Cancer
AstraZeneca 400
Not applicableLooking for participantsNCT07691697
What this trial is testing

PSMA PET-Staged Comprehensive Progression-Directed Radiotherapy for Limited Progression in Prostate Cancer

Who this might be right for
Oligoprogressive Prostate CancerMetastatic Prostate Cancer
Affidea Nu-med Center of Oncological DIagnostics and Therapy 1,000
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07645326
What this trial is testing

RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Georgetown University 108
Early research (Phase 1)Looking for participantsNCT05997615
What this trial is testing

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

Who this might be right for
Hormone-refractory Prostate Cancer
Astellas Pharma Global Development, Inc. 437
Large-scale testing (Phase 3)Looking for participantsNCT05352178
What this trial is testing

Metastasis-directed Therapy for Oligorecurrent Prostate Cancer

Who this might be right for
Prostate CancerProstate Cancer RecurrentProstate Cancer Metastatic+4 more
Universitaire Ziekenhuizen KU Leuven 873
Not applicableLooking for participantsNCT07560748
What this trial is testing

Prospective Prostate Cancer Infrastructure

Who this might be right for
High Risk Localized Prostate CancerSynchronous Metastatic Hormone-Sensitive Prostate Cancer
Radboud University Medical Center 700
Not applicableLooking for participantsNCT06473259
What this trial is testing

Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients

Who this might be right for
Prostate CancerHormone Sensitive Prostate CancerMetastatic Tumor
Santa Chiara Hospital 3,000
Early research (Phase 1)Active Not RecruitingNCT06229366
What this trial is testing

[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Prostate CancerMetastatic Castration-resistant Prostate CancerOligometastatic Prostate Carcinoma+1 more
Eli Lilly and Company 142
Not applicableLooking for participantsNCT06661122
What this trial is testing

Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Low-volume Metastasis
Bayer 100
Large-scale testing (Phase 3)Ended earlyNCT04409288
What this trial is testing

Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer

Who this might be right for
Prostate Cancer
Chinese University of Hong Kong 74
Testing effectiveness (Phase 2)Active Not RecruitingNCT03361735
What this trial is testing

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Who this might be right for
Prostate Adenocarcinoma
City of Hope Medical Center 25
Next Page